FDA Concerned By Shrinking Vaccine Supplier Pool, CBER's Zoon Says
Executive Summary
The potential for vaccine manufacturers to exit the business is "very troubling" to FDA, Center for Biologics Evaluation & Research Director Kathryn Zoon, PhD, told the Regulatory Affairs Professionals Society annual meeting in Washington, D.C. Oct. 4.
You may also be interested in...
Aventis To Increase Fluzone Supply As Wyeth’s FluShield Exits Market
Aventis-Pasteur is in discussions with FDA and the Centers for Disease Control & Prevention on ways to increase the supply of its influenza vaccine Fluzone following Wyeth's decision to discontinue FluShield
Aventis To Increase Fluzone Supply As Wyeth’s FluShield Exits Market
Aventis-Pasteur is in discussions with FDA and the Centers for Disease Control & Prevention on ways to increase the supply of its influenza vaccine Fluzone following Wyeth's decision to discontinue FluShield
Bioterrorism Vaccines: Liability Limits, Federalization Under Consideration
The Biotechnology Industry Organization is urging Congress to limit the liability of manufacturers who enter the vaccine production business in the interest of preparedness against potential bioterrorism attacks.